Pathogenesis-Guided Biomarker Assessment: A Shift in Prostate Cancer Diagnostics

Area of Science:

• Oncology
• Biomarker Discovery
• Pathology

Background:

• Prostate cancer diagnosis faces challenges due to inter-observer variability and ambiguous results.
• Current biomarkers like Prostate-Specific Antigen (PSA) and Alpha-methylacyl CoA racemase (AMACR) exhibit limited specificity and clinical reliability.
• Morphological assessment alone is insufficient for accurate prostate cancer diagnosis.

Purpose of the Study:

• To introduce a novel pathogenesis-guided biomarker discovery strategy for prostate cancer.
• To present a clinically validated biomarker panel (Appl-1, Sortilin, and Syndecan-1) for improved diagnostic accuracy.
• To highlight the potential of these biomarkers in enhancing prognostic utility for prostate cancer patients.

Main Methods:

• A pathogenesis-guided strategy was employed for biomarker discovery, focusing on the endosome-lysosome system.
• A multidisciplinary approach was utilized to identify and validate the biomarker panel.
• Clinical validation and implementation as a lab-developed test (LDT) in U.S. practice were conducted.

Main Results:

• The developed biomarker panel, comprising Appl-1, Sortilin, and Syndecan-1, demonstrates enhanced diagnostic precision.
• These biomarkers reflect fundamental biological processes, offering improved prognostic utility for prostate cancer.
• The panel has been successfully implemented in U.S. clinical practice as an LDT.

Conclusions:

• The novel biomarker panel offers a significant advancement over traditional diagnostic methods for prostate cancer.
• The pathogenesis-guided discovery approach provides a robust framework for developing clinically relevant biomarkers.
• This strategy represents a new diagnostic standard, integrating mechanistic understanding with practical clinical application for prostate cancer management.